KR101950526B1 - 조혈 줄기세포의 생착을 강화하기 위한 방법 - Google Patents

조혈 줄기세포의 생착을 강화하기 위한 방법 Download PDF

Info

Publication number
KR101950526B1
KR101950526B1 KR1020137021164A KR20137021164A KR101950526B1 KR 101950526 B1 KR101950526 B1 KR 101950526B1 KR 1020137021164 A KR1020137021164 A KR 1020137021164A KR 20137021164 A KR20137021164 A KR 20137021164A KR 101950526 B1 KR101950526 B1 KR 101950526B1
Authority
KR
South Korea
Prior art keywords
treprostinil
bone marrow
cells
stem cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137021164A
Other languages
English (en)
Korean (ko)
Other versions
KR20140005956A (ko
Inventor
마이클 프레이스무스
에바-마리아 제베딘-브란들
크리스티안 베르크마이어
필자 후세인
Original Assignee
에스씨아이팜 에스에이알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101950526(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에스씨아이팜 에스에이알엘 filed Critical 에스씨아이팜 에스에이알엘
Publication of KR20140005956A publication Critical patent/KR20140005956A/ko
Application granted granted Critical
Publication of KR101950526B1 publication Critical patent/KR101950526B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
KR1020137021164A 2011-01-13 2012-01-13 조혈 줄기세포의 생착을 강화하기 위한 방법 Active KR101950526B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11150835 2011-01-13
EP11150835.4 2011-01-13
PCT/EP2012/050484 WO2012095511A1 (en) 2011-01-13 2012-01-13 Method for enhancing engraftment of haematopoetic stem cells

Publications (2)

Publication Number Publication Date
KR20140005956A KR20140005956A (ko) 2014-01-15
KR101950526B1 true KR101950526B1 (ko) 2019-02-20

Family

ID=44146841

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137021164A Active KR101950526B1 (ko) 2011-01-13 2012-01-13 조혈 줄기세포의 생착을 강화하기 위한 방법

Country Status (19)

Country Link
US (1) US10213464B2 (https=)
EP (1) EP2663313B1 (https=)
JP (2) JP6110309B2 (https=)
KR (1) KR101950526B1 (https=)
CN (1) CN103379907B (https=)
AU (1) AU2012206517B2 (https=)
BR (1) BR112013017878B1 (https=)
CA (1) CA2824113C (https=)
CL (1) CL2013002034A1 (https=)
DK (1) DK2663313T3 (https=)
EA (1) EA033717B1 (https=)
ES (1) ES2693622T3 (https=)
IL (1) IL227331A (https=)
PL (1) PL2663313T3 (https=)
PT (1) PT2663313T (https=)
SG (1) SG191908A1 (https=)
UA (1) UA113284C2 (https=)
WO (1) WO2012095511A1 (https=)
ZA (1) ZA201304743B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2879682B1 (en) * 2012-08-01 2018-03-21 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
AU2015217142B2 (en) * 2014-02-12 2020-04-09 7 Hills Pharma LLC Compositions and methods to improve the homing and grafting of hematopoetic stem cells
CA2946747A1 (en) * 2014-04-23 2015-10-29 Texas Heart Institute Methods of enhancing stem cell engraftment
US10226465B2 (en) * 2015-01-27 2019-03-12 Scipharm Sàrl Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
CN109727671B (zh) * 2018-12-28 2021-07-09 广东省心血管病研究所 一种鉴定造血干细胞移植术效果的信息分析系统及方法
WO2025172541A1 (en) 2024-02-15 2025-08-21 Aop Orphan Pharmaceuticals Gmbh New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6242482B1 (en) * 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
US8696564B2 (en) 2004-07-09 2014-04-15 Cardiac Pacemakers, Inc. Implantable sensor with biocompatible coating for controlling or inhibiting tissue growth
US20070065414A1 (en) * 2005-09-16 2007-03-22 Boston Scientific Scimed, Inc. Enhanced delivery of cells
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
US8575175B2 (en) * 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
CN102164487A (zh) * 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
CN108379292A (zh) 2008-11-06 2018-08-10 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
WO2010108028A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
RS53234B (sr) * 2009-08-07 2014-08-29 Scipharm Sàrl Kompozicija za lečenje cistične fibroze

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Otsuka, H. et al., Ann Vasc Surg (2006) 20(5):645-652

Also Published As

Publication number Publication date
EP2663313A1 (en) 2013-11-20
JP2017046707A (ja) 2017-03-09
CN103379907B (zh) 2018-01-09
ES2693622T3 (es) 2018-12-13
JP2014507409A (ja) 2014-03-27
ZA201304743B (en) 2014-09-25
DK2663313T3 (en) 2018-11-26
UA113284C2 (xx) 2017-01-10
NZ612450A (en) 2015-03-27
BR112013017878A8 (pt) 2018-01-09
US20130344038A1 (en) 2013-12-26
AU2012206517A1 (en) 2013-08-01
IL227331A0 (en) 2013-09-30
US10213464B2 (en) 2019-02-26
IL227331A (en) 2017-12-31
EA201300817A1 (ru) 2013-11-29
SG191908A1 (en) 2013-08-30
PT2663313T (pt) 2018-10-23
CL2013002034A1 (es) 2014-03-21
BR112013017878A2 (https=) 2017-08-15
CN103379907A (zh) 2013-10-30
JP6110309B2 (ja) 2017-04-05
KR20140005956A (ko) 2014-01-15
PL2663313T3 (pl) 2019-01-31
EP2663313B1 (en) 2018-08-08
EA033717B1 (ru) 2019-11-19
WO2012095511A1 (en) 2012-07-19
AU2012206517B2 (en) 2016-12-01
CA2824113A1 (en) 2012-07-19
BR112013017878B1 (pt) 2021-08-31
CA2824113C (en) 2020-04-14

Similar Documents

Publication Publication Date Title
KR101950526B1 (ko) 조혈 줄기세포의 생착을 강화하기 위한 방법
CA2973146C (en) Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
US9522917B2 (en) Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
US20120202288A1 (en) Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
NZ612450B2 (en) Method for enhancing engraftment of haematopoetic stem cells
HK1186389A (en) Method for enhancing engraftment of haematopoetic stem cells
HK1186389B (en) Method for enhancing engraftment of haematopoetic stem cells
HK1241742B (en) Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
WO2025172541A1 (en) New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130809

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180426

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181025

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180426

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20181025

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180622

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20161228

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20181207

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20181114

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20181025

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20180622

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20161228

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190214

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190214

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220203

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220203

Start annual number: 4

End annual number: 4